^
    over1year
    B7-H3 CAR-T for Recurrent or Refractory Glioblastoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jul 2024 --> Aug 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    temozolomide • BP102
    over1year
    Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jul 2022 --> May 2024 | Trial primary completion date: May 2022 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    temozolomide • BP102